PARP Inhibitors in BRCA Gene-Mutated Ovarian Cancer and Beyond

被引：38

作者：

Banerjee, Susana ^{[2
]}

Kaye, Stan ^{[1
]}

机构：

[1] Royal Marsden NHS Fdn Trust, Div Clin Studies, Inst Canc Res, Drug Dev Unit, Sutton SM2 5PT, Surrey, England

[2] Royal Marsden NHS Fdn Trust, Gynaecol Unit, Sutton SM2 5PT, Surrey, England

来源：

CURRENT ONCOLOGY REPORTS | 2011年 / 13卷 / 06期

关键词：

PARP inhibitors; Ovarian cancer; BRCA; Olaparib; Endometrial; POLY(ADP-RIBOSE) POLYMERASE INHIBITOR; MUTANT-CELLS; TUMOR; MUTATIONS; CARCINOMA; FEATURES; DELETION; REPAIR;

D O I：

10.1007/s11912-011-0193-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Poly(ADP-ribose)polymerase (PARP) inhibitors are showing considerable promise for the treatment of BRCA mutation-associated ovarian and breast cancer. This approach exploits a synthetic lethal strategy to target the specific DNA repair pathway in cancers that harbor mutations in the BRCA1 or BRCA2 genes. Accumulating evidence suggests that PARP inhibitors may have a wider application in the treatment of sporadic, high-grade serous ovarian cancers and other cancers including endometrial cancer. In this review, we discuss the clinical development of PARP inhibitors in ovarian cancer and explore challenges that need to be addressed if the full potential of these agents is to be realized.

引用

页码：442 / 449

页数：8

共 50 条

[21] PARP INHIBITORS IN OVARIAN CANCER THERAPY
Pisula, Agata
Sienicka, Agnieszka
Dobrowolska-Redo, Agnieszka
Kacperczyk-Bartnik, Joanna
Romejko-Wolniewicz, Ewa
PROSPECTS IN PHARMACEUTICAL SCIENCES, 2024, 22 (02): : 71 - 74
[22] PARP inhibitors in the treatment of ovarian cancer
Zeimet, Alain G.
Wieser, Verena
Knoll, Katharina
Reimer, Daniel
Marth, Christian
MEMO-MAGAZINE OF EUROPEAN MEDICAL ONCOLOGY, 2020, 13 (02) : 198 - 201
[23] PARP Inhibitors for the Treatment of Ovarian Cancer
Cortesi, Laura
Toss, Angela
Cucinotto, Iole
CURRENT CANCER DRUG TARGETS, 2018, 18 (09) : 877 - 893
[24] PARP inhibitor treatment of advanced breast cancer beyond the BRCA-mutated type: a meta-analysis
Yan, Feifei
Jiang, Qi
He, Mengye
Shen, Peng
FUTURE ONCOLOGY, 2021, 17 (18) : 2381 - 2393
[25] Candidate biomarkers of PARP inhibitor sensitivity in ovarian cancer beyond the BRCA genes
Hodgson, Darren R.
Dougherty, Brian A.
Lai, Zhongwu
Fielding, Anitra
Grinsted, Lynda
Spencer, Stuart
O'Connor, Mark J.
Ho, Tony W.
Robertson, Jane D.
Lanchbury, Jerry S.
Timms, Kirsten M.
Gutin, Alexander
Orr, Maria
Jones, Helen
Gilks, Blake
Womack, Chris
Gourley, Charlie
Ledermann, Jonathan
Barrett, J. Carl
BRITISH JOURNAL OF CANCER, 2018, 119 (11) : 1401 - 1409
[26] PARP inhibitors in the ovarian cancer therapy
Kruczala, Maksymilian A.
Grela-Wojewoda, Aleksandra
Cedrych, Ida
GINEKOLOGIA POLSKA, 2016, 87 (02) : 131 - 134
[27] MiR-181a targets STING to drive PARP inhibitor resistance in BRCA- mutated triple-negative breast cancer and ovarian cancer
Bustos, Matias A.
Yokoe, Takamichi
Shoji, Yoshiaki
Kobayashi, Yuta
Mizuno, Shodai
Murakami, Tomohiro
Zhang, Xiaoqing
Sekhar, Sreeja C.
Kim, Soomin
Ryu, Suyeon
Knarr, Matthew
Vasilev, Steven A.
Difeo, Analisa
Drapkin, Ronny
Hoon, Dave S. B.
CELL AND BIOSCIENCE, 2023, 13 (01)
[28] PARP inhibitors decrease response to subsequent platinum-based chemotherapy in patients with BRCA mutated ovarian cancer
Rose, Peter G.
Yao, Meng
Chambers, Laura M.
Mahdi, Haider
DeBernardo, Robert
Michener, Chad M.
AlHilli, Miriam
Ricci, Stephanie
Vargas, Roberto
ANTI-CANCER DRUGS, 2021, 32 (10) : 1086 - 1092
[29] PARP-inhibitors in epithelial ovarian cancer: Actual positioning and future expectations
Vanacker, Helene
Harter, Philipp
Labidi-Galy, Sana Intidhar
Banerjee, Susana
Oaknin, Ana
Lorusso, Domenica
Ray-Coquard, Isabelle
CANCER TREATMENT REVIEWS, 2021, 99
[30] PARP Inhibitors in Epithelial Ovarian Cancer: State of Art and Perspectives of Clinical Research
Gadducci, Angiolo
Guerrieri, Maria Elena
ANTICANCER RESEARCH, 2016, 36 (05) : 2055 - 2064

← 1 2 3 4 5 →